Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.
Karim Fizazi
Consultant or Advisory Role - Ipsen
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Honoraria - Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi
Gedske Daugaard
No relevant relationships to disclose
Joaquim Bellmunt
Consultant or Advisory Role - Ipsen
Nathalie Germann
Employment or Leadership Position - Ipsen
Eric Chetaille
Employment or Leadership Position - Ipsen
Stock Ownership - Ipsen
Honoraria - Ipsen